10-Q: Moderna Reports Q2 Revenue Decline Amid Vaccine Market Shift, Advances Key Pipeline Programs

Moderna, Inc. reported a significant decrease in net product sales and total revenue for the second quarter and first half of 2025, while simultaneously advancing its respiratory virus vaccine portfolio with new FDA approvals and positive clinical trial results for its seasonal flu vaccine.

Summary

• Net product sales for the second quarter of 2025 were $114 million, a 38% decrease from $184 million in the same period of 2024.
• Total revenue for the second quarter of 2025 was $142 million, down 41% from $241 million in Q2 2024.
• Net loss for the second quarter of 2025 improved to $(825) million, compared to a net loss of $(1,279) million in Q2 2024.
• For the six months ended June 30, 2025, net product sales were $200 million, a 43% decrease from $351 million in the prior year period.
• Total revenue for the first half of 2025 was $250 million, a 39% decrease from $408 million in the first half of 2024.
• Net loss for the first half of 2025 was $(1,796) million, an improvement from $(2,454) million in the first half of 2024.
• Research and development expenses decreased by 43% to $700 million in Q2 2025 and by 32% to $1,556 million in the first half of 2025, reflecting cost management and portfolio prioritization.
• Selling, general and administrative expenses decreased by 14% to $230 million in Q2 2025 and by 18% to $442 million in the first half of 2025.
• Cost of sales as a percentage of net product sales increased significantly to 105% in Q2 2025 and 104% in the first half of 2025, up from 62% and 60% respectively in 2024, primarily due to lower net product sales.
• FDA approved mNEXSPIKE (next-generation COVID-19 vaccine) in May 2025 for individuals aged 65+ and 12-64 with risk factors.
• FDA approved expanded use of mRESVIA (RSV vaccine) in June 2025 for adults aged 18-59 at increased risk for RSV disease.
• FDA approved Spikevax for children six months through 11 years at increased risk for COVID-19 disease in July 2025.
• Positive Phase 3 efficacy study results for mRNA-1010 (seasonal influenza vaccine candidate) showed a relative vaccine efficacy of 26.6% compared to a licensed standard-dose seasonal influenza vaccine.
• The U.S. Department of Health and Human Services (HHS) terminated the award for late-stage development of mRNA-based pandemic influenza vaccines (H5 program) in May 2025.
• Cash, cash equivalents, and investments totaled $7,505 million as of June 30, 2025, down from $9,519 million at December 31, 2024.
• The company has a diverse pipeline of 30 development candidates across 39 programs, with 35 currently in clinical studies.

Sentiment

Score: 4

Explanation: The sentiment is moderately negative due to significant declines in revenue and continued net losses, coupled with high cost of sales as a percentage of revenue. While there are positives in pipeline advancements and cost control, the core commercial performance is weak, and the termination of a key government contract adds uncertainty. The company's financial position is stable for the near term, but the path to profitability remains challenging.

Positives

• Net loss significantly improved, decreasing by 35% in Q2 2025 and 27% in the first half of 2025, reflecting effective cost management.
• Research and development expenses decreased substantially by 43% in Q2 2025 and 32% in the first half of 2025 due to disciplined cost management and portfolio prioritization.
• Selling, general and administrative expenses decreased by 14% in Q2 2025 and 18% in the first half of 2025, indicating ongoing commitment to operating efficiency.
• FDA approval of mNEXSPIKE (next-generation COVID-19 vaccine) in May 2025 expands the commercial product portfolio.
• Expanded FDA approval for mRESVIA (RSV vaccine) in June 2025 to include adults aged 18-59 at increased risk broadens the target market.
• FDA approval of Spikevax for children aged six months through 11 years in July 2025 further expands its indication.
• Positive Phase 3 efficacy results for mRNA-1010 (seasonal influenza vaccine) demonstrated superiority with a relative vaccine efficacy of 26.6% compared to a licensed standard-dose vaccine.
• Progress in the oncology portfolio with the Phase 3 clinical trial for adjuvant melanoma fully enrolled for intismeran autogene (INT) in collaboration with Merck.
• Advancements in rare disease therapeutics, including mRNA-3927 for Propionic Acidemia (PA) showing potential decreases in metabolic decompensation events, and mRNA-3705 for Methylmalonic Acidemia (MMA) selected for the FDA's START pilot program with a pivotal study expected in 2025.
• The company believes its cash, cash equivalents, and investments are sufficient to fund operations and capital expenditures for at least the next 12 months.

Negatives

• Net product sales decreased significantly by 38% in Q2 2025 and 43% in the first half of 2025, primarily due to lower COVID vaccination rates and a lower average selling price in the U.S. market.
• Total revenue declined by 41% in Q2 2025 and 39% in the first half of 2025.
• Cost of sales as a percentage of net product sales increased dramatically to 105% in Q2 2025 and 104% in the first half of 2025, up from 62% and 60% respectively in 2024, driven by lower net product sales and fixed manufacturing costs.
• Inventory write-downs of $38 million in Q2 2025 and $80 million in the first half of 2025, mainly due to inventory in excess of expected demand and shelf-life expiration.
• Losses on firm purchase commitments of $7 million in Q2 2025 and $17 million in the first half of 2025, primarily related to excess raw material purchase commitments.
• Termination of the U.S. Department of Health and Human Services (HHS) award for late-stage development of mRNA-based pandemic influenza vaccines (H5 program) in May 2025.
• Voluntary withdrawal of the Biologics License Application (BLA) for the flu+COVID combination vaccine (mRNA-1083) to await efficacy data from another trial.

Risks

• Ability to drive use of Spikevax, mNEXSPIKE, and mRESVIA and increase market share in evolving commercial COVID and RSV vaccine markets.
• Impact of evolving markets on financial returns and the ability to effectively compete in such markets.
• Uncertainty around demand for COVID and RSV vaccines, leading to variability in cost of sales as a percentage of net product sales due to fixed manufacturing costs.
• Ability to obtain and maintain regulatory approval for product candidates across the portfolio.
• Ability to successfully launch and commercialize products and the timing of launches.
• Ability of the company and third parties to successfully manufacture, supply, and distribute vaccine products at scale.
• Scope of protection for intellectual property rights and outcomes of pending legal proceedings related to intellectual property.
• Timing of initiation, progress, completion, results, and cost of clinical trials, preclinical studies, and research and development programs.
• Potential for unforeseen expenses, difficulties, complications, and delays that may adversely affect the business.
• Decline in customer demand for COVID vaccine continuing into 2025, reflecting market transition to a seasonal commercial pattern.
• Continued negative cash flows from operations in upcoming periods due to investment in the business for future product launches.
• Litigation risks including patent-infringement actions against Pfizer Inc., BioNTech SE, Alnylam Pharmaceuticals, Arbutus Biopharma Corporation, Genevant Sciences GmbH, GlaxoSmithKline Biologicals SA, and Northwestern University.
• Shareholder class action and shareholder derivative litigation related to statements about the RSV vaccine (mRNA-1345).

Future Outlook

The company anticipates seasonal fluctuations in demand for its COVID and RSV vaccines, with higher sales expected during the fall and winter seasons. A decline in net product sales for the full year 2025 compared to 2024 is expected due to lower vaccination rates and increased competition. Research and development expenses are projected to decrease in 2025 due to disciplined cost management, portfolio prioritization, and operational efficiencies. Selling, general and administrative expenses are also expected to see a modest reduction. The company foresees continued negative cash flows from operations in upcoming periods due to ongoing investments in the business for future product launches. Cash, cash equivalents, and investments are believed to be sufficient to fund projected operations and capital expenditures through at least the next 12 months.

Management Comments

• We will explore alternatives for late-stage development and manufacturing of the H5 program consistent with our strategic commitment to pandemic preparedness.
• We continue to anticipate a reduction in research and development expenses in 2025 compared to 2024, driven by disciplined cost management, portfolio prioritization, and a focused approach to pipeline execution.
• We are implementing operational efficiencies across the organization, including meaningful resourcing adjustments to align with the current stage of our pipeline and to support long-term sustainability.
• We continue to anticipate a modest reduction in selling, general and administrative expenses in 2025 compared to 2024, reflecting our ongoing commitment to operating efficiency as we expand our global commercial, regulatory, sales and marketing infrastructure.
• We are investing in digital capabilities and leveraging artificial intelligence technologies, while making organizational refinements to better align resources with the evolving needs of the business and support long-term scalability.
• We believe that our cash, cash equivalents, and investments as of June 30, 2025, together with cash expected to be generated from product sales, will be sufficient to enable us to fund our projected operations and capital expenditures through at least the next 12 months from the issuance of these financial statements.

Industry Context

The company's performance reflects the ongoing transition of the COVID-19 vaccine market from a pandemic-driven emergency response to a seasonal commercial market, characterized by lower vaccination rates and increased competition. This shift is impacting net product sales and necessitating strategic adjustments in manufacturing capacity and cost structures. Moderna is actively expanding its respiratory virus vaccine portfolio beyond COVID-19 with RSV and seasonal influenza candidates, aligning with a broader industry trend towards comprehensive respiratory protection. The continued investment in oncology and rare disease therapeutics indicates a strategic diversification beyond infectious diseases, positioning the company for long-term growth in high-value therapeutic areas, a common strategy among large biotechnology firms.

Comparison to Industry Standards

• The Phase 3 study for mNEXSPIKE (mRNA-1283) demonstrated non-inferior vaccine efficacy compared to Spikevax (mRNA-1273), with a 9.3% higher relative vaccine efficacy in the overall population and 13.5% higher relative efficacy in adults aged 65 and older, indicating a potentially improved profile over its predecessor.
• The Phase 3 efficacy study of mRNA-1010 (seasonal influenza vaccine) achieved a relative vaccine efficacy (rVE) of 26.6% (95% CI: 16.7%, 35.4%) compared to a licensed standard-dose seasonal influenza vaccine, demonstrating superiority against an established market benchmark.

Legal Proceedings

• Patent-infringement actions brought by Moderna against Pfizer Inc., BioNTech SE, and related entities in multiple jurisdictions (U.S., Germany, Netherlands, UK, Ireland, Belgium) concerning mRNA platform technology and vaccine designs.
• Patent-infringement actions filed by Alnylam Pharmaceuticals against Moderna in the U.S. District Court for the District of Delaware concerning cationic lipids (one case decided in Moderna's favor on appeal, second case pending).
• Patent-infringement actions brought by Arbutus Biopharma Corporation and Genevant Sciences GmbH against Moderna in the U.S. District Court for the District of Delaware, Canada, Japan, Switzerland, and the Unified Patent Court (UPC) concerning lipid nanoparticles (U.S. trial rescheduled to March 9, 2026).
• Patent-infringement lawsuits filed by GlaxoSmithKline Biologicals SA (GSK) against Moderna in the U.S. District Court for the District of Delaware and the UPC concerning liposomes and modified liposomes for RNA delivery.
• A complaint filed by Northwestern University against Moderna in the U.S. District Court for the District of Delaware asserting U.S. patents concerning lipid nanoparticle technology.
• Shareholder class action and shareholder derivative litigation pending in the U.S. District Court for the District of Massachusetts related to statements about the RSV vaccine (mRNA-1345).

Stakeholder Impact

• Shareholders: Impacted by significant revenue decline and continued net losses, but also by pipeline advancements and cost control efforts. The company has a $1.7 billion share repurchase authorization outstanding.
• Employees: Affected by headcount reductions and organizational refinements aimed at aligning resources and improving efficiency.
• Customers (Healthcare Providers, Governments, Individuals): Benefit from new and expanded vaccine approvals (mNEXSPIKE, mRESVIA, Spikevax) offering broader protection and choice.
• Suppliers and Manufacturers: Impacted by adjustments to demand forecasts, leading to inventory write-downs and losses on firm purchase commitments, as well as wind-down costs for certain contracts.
• Creditors: The company's strong cash and investment position (over $7.5 billion) provides financial stability, mitigating immediate concerns for creditors.

Next Steps

• Make mNEXSPIKE available in the U.S. for the 2025-2026 respiratory virus season.
• Supply mRESVIA for both approved adult populations in the U.S. for the 2025-2026 respiratory virus season.
• Explore alternatives for late-stage development and manufacturing of the H5 pandemic influenza program.
• Submit mRNA-1010 (seasonal influenza vaccine) data for publication, present data at medical conferences, and prepare for FDA approval filing.
• Engage with regulators on data requirements for resubmitting the Biologics License Application (BLA) for mRNA-1083 (flu+COVID combination vaccine).
• Anticipate a Phase 3 final analysis for the CMV vaccine candidate (mRNA-1647) in 2025.
• Continue enrolling patients in Phase 3 studies for intismeran autogene (INT) in non-small cell lung cancer (NSCLC) and Phase 2 studies for bladder cancer and metastatic melanoma.
• Continue accruing cases for the Phase 3 study of the trivalent norovirus vaccine candidate (mRNA-1403).
• Expect to start a registrational study for the Methylmalonic Acidemia (MMA) therapeutic (mRNA-3705) in 2025.
• Continue to invest in internal manufacturing capabilities to improve cost control and support potential future product launches.
• Implement operational efficiencies and organizational refinements to align resources with evolving business needs and support long-term scalability.

Key Dates

Recommendation

While the company reported a substantial decline in net product sales and continued net losses, indicating challenges in the commercial vaccine market, it also demonstrated significant progress in its pipeline with multiple FDA approvals for new and expanded vaccine indications (mNEXSPIKE, mRESVIA, Spikevax) and positive Phase 3 data for its seasonal flu vaccine. Cost control measures are also evident in reduced R&D and SG&A expenses. The termination of BARDA funding for the pandemic flu vaccine is a setback, but the company is exploring alternatives. The ongoing intellectual property litigation adds uncertainty. Given the mixed financial performance but strong pipeline advancements and strategic cost management, a 'hold' recommendation is appropriate, suggesting investors monitor the commercial uptake of new vaccines and further pipeline developments.

Keywords

Moderna, mRNA, Vaccines, COVID-19, RSV, Influenza, Oncology, Rare Disease, Biotechnology, Pharmaceutical, SEC Filing, 10-Q, Clinical Trials, FDA Approval, Financial Results, Pipeline